To evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy
Subjects with primary membranous nephropathy pathologically confirmed by renal biopsy;
Subjects with glomerular filtration rate（eGFR） ≥ 45 mL/min/1.73 m2.
If taking Angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists/sodium-glucose cotransporter 2 inhibitors/endothelin inhibitors, a stable dose within 4 weeks before randomization;
Subjects with 24-hour elevated urinary protein in accordance with the prescribed conditions;
Subjects with secondary membranous nephropathy or primary membranous nephropathy whose pathological reports suggest concomitant crescent bodies;
Subjects identified by the investigator as previously resistant to CD20 monoclonal antibody or cyclosporine;
Subjects who have received medication prescribed for membranous nephropathy;
Subjects with concomitant prescribed diseases;
Parallel
B007
DrugB007： Subcutaneous injection was administered on days 1 and 15
Cyclosporin Capsules
DrugCyclosporin Capsules： Orally, 3.5 mg/kg/d；
ORR（Overall Remission Rate）
CRR（Complete Remission Rate）
PRR（Partial Remission Rate）
Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Click on the lead sponsor to view all of their trials.
Shanghai Jiaolian Drug Research and Development Co., Ltd
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Collaborator
